Intercept Pharmaceuticals Inc (NASDAQ:ICPT) – Equities research analysts at Jefferies Group increased their Q1 2018 earnings per share estimates for shares of Intercept Pharmaceuticals in a research note issued on Wednesday. Jefferies Group analyst M. Yee now anticipates that the biopharmaceutical company will post earnings of ($3.24) per share for the quarter, up from their prior forecast of ($3.39). Jefferies Group also issued estimates for Intercept Pharmaceuticals’ Q2 2018 earnings at ($3.18) EPS, Q3 2018 earnings at ($3.12) EPS, Q4 2018 earnings at ($2.91) EPS, FY2018 earnings at ($12.43) EPS and FY2019 earnings at ($10.33) EPS.
Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($4.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.39) by ($1.04). The company had revenue of $37.69 million during the quarter, compared to the consensus estimate of $39.01 million. Intercept Pharmaceuticals had a negative net margin of 275.18% and a negative return on equity of 207.27%. The business’s revenue was up 173.1% on a year-over-year basis. During the same quarter last year, the company earned ($4.84) earnings per share.
Intercept Pharmaceuticals (NASDAQ ICPT) opened at $60.78 on Monday. The company has a debt-to-equity ratio of 3.15, a current ratio of 5.95 and a quick ratio of 5.95. The company has a market capitalization of $1,530.00, a price-to-earnings ratio of -4.23 and a beta of -2.13. Intercept Pharmaceuticals has a one year low of $51.05 and a one year high of $135.59.
Several institutional investors and hedge funds have recently modified their holdings of the company. Macquarie Group Ltd. lifted its stake in shares of Intercept Pharmaceuticals by 95.4% during the fourth quarter. Macquarie Group Ltd. now owns 9,768 shares of the biopharmaceutical company’s stock valued at $571,000 after acquiring an additional 4,768 shares during the period. LPL Financial LLC acquired a new position in shares of Intercept Pharmaceuticals during the fourth quarter valued at $4,464,000. DSC Advisors L.P. acquired a new position in shares of Intercept Pharmaceuticals during the fourth quarter valued at $204,000. Sarissa Capital Management LP acquired a new position in shares of Intercept Pharmaceuticals during the fourth quarter valued at $10,649,000. Finally, Raymond James & Associates acquired a new position in shares of Intercept Pharmaceuticals during the fourth quarter valued at $1,991,000. 78.39% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This story was originally posted by Week Herald and is owned by of Week Herald. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://weekherald.com/2018/02/21/q1-2018-eps-estimates-for-intercept-pharmaceuticals-inc-raised-by-jefferies-group-icpt.html.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.